Company:  ZOGENIX, INC. (ZGNX)
Form Type:  8-K
Filing Date:  1/9/2012 
CIK:  0001375151 
Address:  12400 HIGH BLUFF DRIVE
SUITE 650
 
City, State, Zip:  SAN DIEGO, California 92130 
Telephone:  (858) 259-1165 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$2.84  
Change: 
0.03 (1.07%)  
Trade Time: 
04:00 PM EST  
Market Cap: 
$396.29M
Description of Business
We are a pharmaceutical company committed to developing and commercializing therapies that address specific clinical needs for people living with pain-related conditions and central nervous system disorders who need innovative treatment alternatives to help them return to normal daily functioning. On October 25, 2013, we received marketing approval from the U.S. Food and Drug Administration, or FDA, for Zohydro� ER (hydrocodone bitartrate) extended-release capsules, an opioid agonist, extended-release oral formulation of hydrocodone without acetaminophen, for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Zohydro ER is the first extended-release oral formulation of hydrocodone without acetaminophen. Zohydro ER was launched on March 3, 2014. In addition, we are commercializing Sumavel� DosePro� (sumatriptan injection) Needle-free Delivery System.
Register for EDGAR Pro and access this filing in:     
  FORM 8-K
    SECTION 2 FINANCIAL INFORMATION
      Item 2.02. Results of Operations and Financial Condition.
    SECTION 7 REGULATION FD
      Item 7.01. Regulation FD Disclosure.
    SECTION 9 FINANCIAL STATEMENTS AND EXHIBITS
      Item 9.01. Financial Statements and Exhibits.
    SIGNATURES
    EXHIBIT INDEX
  EXHIBIT 99.1
BROKERAGE PARTNERS